Equal Health and Rights Access Advocacy Initiative EHRAAI

Email

ehraai@gmail.com

Phone

T: +2347033517199

Web

https://www.linkedin.com/in/ehraa-initiative-353153161/

Address

13,Megida Ogunbewon, Street,Onimaba Estate,Off Igando-Ikotun Road, Alimosho, Lagos, Nigeria
About Equal Health and Rights Access Advocacy Initiative EHRAAI

Equal Health and Rights Access Advocacy Initiative EHRAAI is a youth and key population – led organisation working on harm reduction, research and human rights advocacy in Nigeria. They are a non- profit, non- governmental organisation situated in Lagos and founded in February 2014 with geographical coverage within South-West (Lagos & Oyo) and North Central (Kwara) part of Nigeria.

They make significant strides in hepatitis B and C interventions at the community level in Nigeria.

 

Here are some of their activities:

  • Community Education and Sensitisation: EHRAAI conducts door-to-door campaigns, radio sessions, and community outreach programmes to educate people about hepatitis B and C, their transmission, prevention, and treatment options.
  • Free Screening and Vaccination: They offer free hepatitis B screening and vaccination services to community members, particularly targeting pregnant women, lactating mothers, and children under five years old.
  • Capacity Building: EHRAAI trains community health workers, village health teams, and other stakeholders to enhance their knowledge and skills in hepatitis B and C management and prevention.
  • Advocacy and Policy Engagement: They engage with policymakers, healthcare providers, and influencers to advocate for hepatitis B birth dose vaccination, improved healthcare infrastructure, and increased access to testing and treatment services.
  • Referral and Linkage: EHRAAI establishes referral networks to connect individuals diagnosed with hepatitis B or C to treatment centres, ensuring they receive proper care and support.
  • Research and Data Collection: They conduct research studies to understand the prevalence and risk factors of hepatitis B and C in specific communities, informing evidence-based interventions. EHRAAI’s efforts are crucial in reducing the burden of hepatitis B and C in Nigeria. By empowering communities with knowledge, increasing access to screening and vaccination, and advocating for policy changes, they are working towards a hepatitis-free society.

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close